New England Journal of Medicine

A 10-year study found arthroscopic knee surgery for degenerative cartilage tears provides little benefit and may accelerate osteoarthritis and reoperation rates. Patients who received the procedure or a sham surgery showed similar outcomes, with surgery patients experiencing more pain. The study challenges the efficacy of the surgery, which is declining in use in Finland and the U.S.

The US faces an estrogen patch shortage, impacting menopausal women's access to hormone therapy. A study in the New England Journal of Medicine suggests that certain men could also benefit from the treatment.

A common drug, Tranexamic acid, may enhance surgical safety by reducing blood loss and the need for blood transfusions. It is commonly used in cardiac and orthopedic surgeries to prevent surgical blood clots, according to a report in the New England Journal of Medicine.

Revolution Medicines' pancreatic cancer drug daraxonrasib showed a 60% reduction in mortality risk compared to chemotherapy, with a median survival of 13.2 months. China's biotechnology sector is rapidly growing, marked by a first-ever China-only clinical trial presentation at the ASCO conference.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a clinical trial. The drug targets a mutated protein present in over 90% of pancreatic cancer cases and showed fewer severe side effects, with patients reporting better quality of life.

A novel pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a study of 500 patients. The drug, which targets a mutated protein common in pancreatic cancer, showed fewer severe side effects and is being considered a new standard of care. The FDA plans to expedite its review, and the Food and Drug Administration is allowing expanded access for eligible patients.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy, with fewer severe side effects. The drug, which targets a mutated protein common in pancreatic cancer, is being fast-tracked for FDA review and has shown improved quality of life for patients.

A new phase 3 clinical trial called PROTEUS found that combining two hormone therapies before and after surgery improved outcomes for high-risk, early-stage prostate cancer patients compared to one hormone therapy. Some oncologists view this as a potential new standard of care, though interpretations of the results vary.

A clinical trial of daraxonrasib, a pancreatic cancer drug developed by Revolution Medicines, showed patients lived nearly twice as long as those receiving standard chemotherapy. Results were presented at the American Society of Clinical Oncology meeting and published in the New England Journal of Medicine.

An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.

An experimental gene-editing drug, VERVE-102, showed a 62% reduction in LDL cholesterol in a Phase I trial with 35 patients, with no serious adverse events reported. The treatment demonstrated sustained effectiveness over 18 months, though a temporary mild liver enzyme increase was observed.

A 74-year-old man in Florida developed a severe flesh-eating bacterial infection after a minor leg cut while swimming, leading to rapid decay of his arm and leg within three days. He was hospitalized with symptoms including darkened skin, gas bubbles under the skin, and a large blood blister, as documented in a case report from the New England Journal of Medicine.